Research programme: bispecific antibodies - Immune Pharmaceuticals

Drug Profile

Research programme: bispecific antibodies - Immune Pharmaceuticals

Alternative Names: Tetravalent bsAb - Immune Pharmaceuticals; Tetravalent IgG1-like bispecific antibody - Immune Pharmaceuticals

Latest Information Update: 30 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Pharmaceuticals Inc
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action B-cell maturation antigen modulators; OX40 receptor modulators; Programmed cell death-1 ligand-1 modulators; Programmed cell death-1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Renal cell carcinoma

Most Recent Events

  • 23 Jan 2017 Immune Pharmaceuticals enters into an exclusive sub-licensing agreement with SATT Sud Est for the development and commercialisation of mono- and bi-specific antibodies for Cancer
  • 23 Jan 2017 Preclinical trials in Renal cell carcinoma in France (Parenteral)
  • 22 Mar 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top